Dizal Pharmaceutical's Zegfrovy has taken the EGFR inhibitor class into new territory after hitting the mark in a phase 3 ...

The FDA has scheduled a public meeting to discuss its Commissioner's National Priority Voucher (CNPV) programme, amid ...

Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes and obesity, as a key patent in India is due to expire ...

California biotech Kali Therapeutics has snagged its first major pharma partner, Sanofi, which is committing $180 million in near-term payments for rights to a T-cell engager (TCE) for autoimmune ...

Valneva and Pfizer's three-dose shot targets the outer surface protein A (OspA) of the Borrelia burgdorfii bacteria that causes the disease, and has previously shown in phase 2 trials that it ...

Earendil Labs has raised an impressive $787 million in financing for its AI-powered drug discovery and development platform, which has already attracted some big-ticket deals with pharma group Sanofi.

After a successful appeal, reimbursement authority NICE has said the companies' files will now be sent back to the appraisal ...

After a strong start to the year, the value of biotech financings has tailed off a little, but March has seen a clutch of $50 ...

February was a light month for agency and consultancy news, but a few interesting changes came through. Read on for the ...

As the FDA released its draft guidance, the NIH said it will invest $150 million in human-based research to develop the tools ...

This breakthrough has accelerated peptide drug development across multiple therapeutic areas, including cardiovascular ...